#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Philadelphia positive chronic myeloid leukaemia Glomerulonephritis acute Li-Fraumeni syndrome Sarcoidosis Ewing's sarcoma recurrent Spinal cord injury cervical Growth hormone deficiency Muscular dystrophy Polymyositis Mycobacterium abscessus infection Kaposi's sarcoma Arterial disorder Mitochondrial DNA depletion Angiosarcoma metastatic Pulmonary sarcoidosis More trials…

    Learn about Rare Diseases

    Pulmonary fibrosis – Diagnostics Pelizaeus-Merzbacher disease – Treatment Wiskott-Aldrich syndrome – Treatment Alexander disease – Trials in Disease MELAS syndrome – Life with Disease IgA nephropathy – Diagnostics Turner’s syndrome – Basic Information Epidermolysis bullosa Mucopolysaccharidosis I – Life with Disease Alport’s syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lidocaine LUNRESERTIB AUR200 Docetaxel Eftrenonacog Alfa Durvalumab LY3841136 SODIUM Tas3351 Belimumab Sonidegib Tegoprubart Damoctocog Alfa Pegol POLYSORBATE 80 Clemastine Fluorescein Sodium Ergocalciferol Bp Levothyroxine Sodium AZD4360 Elebsiran Tiragolumab More therapies…

    Learn about Your Condition

    Eye disorder Prader-Willi syndrome Medulloblastoma Diabetes mellitus Anaemia of chronic disease Chondrosarcoma Metastases to rectum Follicular lymphoma stage II Exudative retinopathy Von Willebrand's disease Craniopharyngioma Dementia Alzheimer's type Small cell lung cancer Chronic spontaneous urticaria Dystonic tremor More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of ALE.

    Recruiting

    2 1 1
    Investigated Drugs:
    • ALE.P03
    France Italy The Netherlands Spain

  • A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

    Recruiting

    2 1
    Investigated Drugs:
    • Ro7790121
    Belgium Denmark France Germany Italy Poland +1

  • A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

    Recruiting

    3 1
    Belgium France Germany Italy The Netherlands Poland +1

  • A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Amivantamab
    • Lazertinib
    Belgium Finland France Germany Greece Italy +3

  • A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • AB521
    • Cabozantinib
    • Placebo
    Czechia France Germany Italy The Netherlands Poland +2

  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Mk-1084
    Austria Belgium France Germany Greece Hungary +5

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    • Cabazitaxel
    • Docetaxel
    Austria Belgium France Germany Greece Italy +3

  • A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Belgium Czechia Denmark Italy The Netherlands Spain +1

  • A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Belzutifan
    • Cabozantinib
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium Croatia Czechia Denmark France +6
Previous Page
1 … 8 9 10 11 12 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!